Evidence map›Paper›PMID 36948020›Full record

ArticleThrombosis research2023

Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA).

Zhihui Zhang, Wei Hong, Qian Wu, Spiridon Tsavachidis, Jian-Rong Li, Christopher I Amos, Chao Cheng, Sarah E Sartain, Vahid Afshar-Kharghan, Jing-Fei Dong and 5 more

Open access · greenAbstract read
In one paragraph

Article in Thrombosis research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Transplant-associated TMA: the conundrum of diagnosis and treatment.Hematology. American Society of Hematology. Education Program · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Zhihui ZhangInstitute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX, United States of America.
Wei HongInstitute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX, United States of America.
Qian WuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Spiridon TsavachidisSection of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States of America.
Jian-Rong LiInstitute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX, United States of America.
Christopher I AmosInstitute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX, United States of America; Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX, United States of America.
Chao ChengInstitute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX, United States of America.
Sarah E SartainSection of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States of America.
Vahid Afshar-KharghanSection of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Jing-Fei DongBloodWorks Northwest Research Institute, Seattle, WA, United States of America.
Pavan BhatrajuDivision of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States of America.
Paul J MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States of America.
Robert S MakarDivision of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA, United States of America; Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
Pavan K BendapudiDivision of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA, United States of America; Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America.
Ang LiSection of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States of America. Electronic address: ang.li2@bcm.edu.
Baylor College of Medicine · USBeth Israel Deaconess Medical Center · USFred Hutch Cancer Center · USBloodworks Northwest · USHouston Institute for Clinical Research · USThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · US

Funding

AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Paul Avillach, Bettina M. Beech · 2021 to 2026
$168.7M
The Assessment of Acute Kidney Injury Sub-phenotypes in the Intensive Care UnitK23DK116967 · NIDDK · UNIVERSITY OF WASHINGTON · PI BHATRAJU, PAVAN KUMAR · 2019 to 2023
$938k
Epidemiology and Biomarkers in Transplant Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Validation Cohort StudyK23HL159271 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Ang Li · 2022 to 2026
$835k
NHLBI NIH HHS K23 HL159271NIDDK NIH HHS K23 DK116967NIH HHS OT2 OD032581
6 · The paper itself

Abstract

The significance of rare germline mutations in transplant-associated thrombotic microangiopathy (TA-TMA) is not well studied. We performed a genetic association study in 100 adult TA-TMA patients vs. 98 post-transplant controls after matching by race, sex, and year. We focused on 5 pathways in complement, von Willebrand factor (VWF) function and related proteins, VWF clearance, ADAMTS13 function and related proteins, and endothelial activation (3641variants in 52 genes). In the primary analysis focused on 189 functional rare variants, no differential variant enrichment was observed in any of the pathways; specifically, 29 % TA-TMA and 33 % controls had at least 1 rare complement mutation. In the secondary analysis focused on 37 rare variants predicted to be pathogenic or likely pathogenic by ClinVar, Complement Database, or REVEL in-silico prediction tool, rare variants in the VWF clearance pathway were found to be significantly associated with TA-TMA (p = 0.008). On the gene level, LRP1 was the only one with significantly increased variants in TA-TMA in both analyses (p = 0.025 and 0.015). In conclusion, we did not find a significant association between rare variants in the complement pathway and TA-TMA; however, we discovered a new signal in the VWF clearance pathway driven by the gene LRP1 among likely pathogenic variants.

Indexed as

Hematopoietic Stem Cell TransplantationThrombotic MicroangiopathiesAdultComplement System ProteinsGerm CellsGerm-Line MutationHumansvon Willebrand FactorComplement System Proteinsvon Willebrand FactorComplement system proteinsGenetic association studiesHematopoietic stem cell transplantationThrombotic microangiopathiesvon Willebrand factor

Identifiers

PMID36948020
PMCPMC10147584
OpenAlexW4324344270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.